Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Cyclin-Dependent Kinase (CDK) 4/6 inhibitors have shown significant clinical activity in cancer patients. However, some concerns regarding rare adverse events (AEs) have occurred including interstitial lung disease (ILD)/pneumonitis, for which data are deficient. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Ma, Zhuo, Sun, Ximu, Feng, Xin, An, Zhuoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873944/
https://www.ncbi.nlm.nih.gov/pubmed/35219113
http://dx.doi.org/10.1016/j.breast.2022.02.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873944/
https://www.ncbi.nlm.nih.gov/pubmed/35219113
http://dx.doi.org/10.1016/j.breast.2022.02.011

Ejemplares similares